BioMarin Pharmaceuticals
BMRN
377 hedge funds and large institutions have $19.5B invested in BioMarin Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 148 increasing their positions, 110 reducing their positions, and 37 closing their positions.
108% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 37
46% more capital invested
Capital invested by funds: $13.4B → $19.5B (+$6.18B)
45% more funds holding in top 10
Funds holding in top 10: 11 → 16 (+5)
35% more repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 110
11% more funds holding
Funds holding: 341 → 377 (+36)
9% less call options, than puts
Call options by funds: $218M | Put options by funds: $240M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$661M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$151M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$124M |
| 4 |
JP Morgan Chase
New York
|
+$105M |
| 5 |
SC
Sculptor Capital
New York
|
+$63.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$164M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$106M |
| 3 |
TG
TCW Group
Los Angeles,
California
|
-$95.9M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$74.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$52.2M |
BMRN Hedge Fund Activity: Q1 2015 in Review
377 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2015, worth a combined $19.5B — up 46% from $13.4B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new BMRN positions and 37 closed out — a net gain of 40 holders — while 148 added to existing stakes and 110 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $661M. The largest seller was Fidelity Investments, cutting an estimated $164M.
- 377 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2015, up from 341 in Q4 2014.
- Funds reported $19.5B of BioMarin Pharmaceuticals stock for Q1 2015, up 46% quarter-over-quarter.
- 77 funds opened new BioMarin Pharmaceuticals positions in Q1 2015 and 37 closed out, a net change of +40 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2015 was T. Rowe Price Associates, an estimated $661M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2015 was Fidelity Investments, an estimated $164M sold.
Based on aggregated 13F filings for Q1 2015.